Early Effect of Pravastatin on Serum Soluble CD40L, Matrix Metalloproteinase-9, and C-Reactive Protein in Patients with Acute Myocardial Infarction
Open Access
- 1 September 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 50 (9), 1696-1699
- https://doi.org/10.1373/clinchem.2003.030940
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Atorvastatin Lowers Plasma Matrix Metalloproteinase-9 in Patients with Acute Coronary SyndromeClinical Chemistry, 2004
- High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL StudyCirculation, 2003
- Reduction in Serum Levels of Adhesion Molecules, Interleukin-6 and C-reactive Protein Following Short-term Low-dose Atorvastatin Treatment in Patients with Non-familial HypercholesterolemiaHormone and Metabolic Research, 2003
- Information for readersAmerican Heart Journal, 2003
- Association Between Enhanced Soluble CD40L and Prothrombotic State in HypercholesterolemiaCirculation, 2002
- Short-term effects of atorvastatin on C-reactive proteinPublished by Oxford University Press (OUP) ,2002
- Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndromeClinica Chimica Acta; International Journal of Clinical Chemistry, 2002
- Effect of Statin Therapy on C-Reactive Protein LevelsJAMA, 2001
- An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In VitroCirculation, 2001
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996